Skip to main navigation menu Skip to main content Skip to site footer
Plant Science Today (PST)

Review Articles

Early Access

The metabolic effect of medicinal plants and synthetic anti-obesity products on human health

DOI
https://doi.org/10.14719/pst.3206
Submitted
14 December 2023
Published
23-08-2024
Versions

Abstract

A significant public health issue is the widespread prevalence of overweight and obesity across all age groups. This common nutritional disorder affects more than general appearance. Obesity is now recognized as a medical condition that necessitates treatment to lower the risk of diabetes and other metabolic diseases. Obesity is a prevalent global health problem that re- requires urgent research and regulatory compliance. While synthetic anti-obesity drugs are available, they pose significant risks of adverse effects and variable outcomes. These drugs,
which include single medications such as orlistat, liraglutide, and Lorcaserin, and combination therapies like naltrexone/bupropion and Phentermine/topiramate are effective in reducing body fat. However, patients often report side effects ranging from mild symptoms like nausea, insomnia, and dizziness to severe complications such as an increased risk of CVD or stroke. Conversely, there is a growing interest in using anti-obesity natural compounds, including single agents such as various types of tea, cinnamon, etc. This review highlights the various mechanisms of anti-obesity action of natural plants and synthetic medications, including metabolism and energy expenditure, appetite suppression, lipid metabolism, gut microbiota, pancreatic lipase inhibition, amylase inhibition, enhancement of insulin sensitivity, inhibition of adipogenesis and thermogenic stimulation. It provides insights into the metabolic effects of both medicinal plants and pharmaceutical drugs on human health, examining their effectiveness and the prevention benefits of each type. Medicinal plants are considered the best alternative for margining obesity due to their cost-effectiveness and minimal adverse effects. While diet mod- ification and increased physical activity through regular exercise are often recommended to prevent obesity, these measures can be challenging for many people. In contrast, the administration of medicinal plants are relatively convenient, making them an accurate and ideal alternative.

References

  1. Singh M, Thrimawithana T, Shukla R et al. Obesity through natural polyphenols: A review. Future Foods. 2020;1(2):100002. https://doi.org/10.1016/j.fufo.2020.100002
  2. WHO. Diet, nutrition and the prevention of chronic diseases: Report of a WHO-FAO expert consultation. In: Proceedings of the Joint. WHO-FAO Expert Consultation on Diet, Nutrition and the Prevention of Chronic Diseases, Geneva, Switzerland. WHO Technical Report Series. 28 January–1 February 2002.
  3. Swift DL, McGee JE, Earnest CP, Carlisle E, Nygard M, Johannsen NM. The effects of exercise and physical activity on weight loss and maintenance. Prog Cardiovasc Dis. 2018;61:206-13. https://doi.org/10.1016/j.pcad.2018.07.014
  4. Vandoni M, Codella R, Pippi R et al. Combating sedentary behaviors by delivering remote physical exercise in children and adolescents with obesity in the COVID-19 era: A narrative review. Nutrients. 2021;13:4459. https://doi.org/10.3390/nu13124459
  5. Toniolo-Barrios M, Pitt L. Mindfulness and the challenges of working from home in times of crisis. Bus Horiz. 2021;64:189-97. https://doi.org/10.1016/j.bushor.2020.09.004
  6. Renehan AG, Tyson M, Egger et al. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569-78. https://doi.org/10.1016/S0140-6736(08)60269-X
  7. Seidell JC. Waist circumference and waist/hip ratio about all-cause mortality, cancer and sleep apnea. Eur J Clin Nutr. 2010;64:35-41. https://doi.org/10.1038/ejcn.2009.71
  8. Roriz C, Karla A, Passos S et al . Anthropometric clinical indicators in the assessment of visceral obesity: An update. Nutr Clín Diet Hosp. 2016;36:168-79.
  9. Reyes-Farias M, Fos-Domenech J, Serra D, Herrero et al. White adipose tissue dysfunction in obesity and aging. Biochem Pharmacol. 2021;192:114723. https://doi.org/10.1016/j.bcp.2021.114723
  10. Nicolaidis S. Environment and obesity. Metabolism. 2019;100:153942. https://doi.org/10.1016/j.metabol.2019.07.006
  11. D’Anneo A, Bavisotto CC, Gammazza et al. Lipid chaperones and associated diseases: A group of chaperonopathies defining a new nosological entity with implications for medical research and practice. Cell Stress Chaperones. 2020;25:805-20. https://doi.org/10.1007/s12192-020-01153-6
  12. Piché ME, Tchernof A, Després JP. Obesity phenotypes, diabetes and cardiovascular diseases. Circ Res. 2020;126:1477-500. https://doi.org/10.1161/CIRCRESAHA.120.316101
  13. Ng ACT, Delgado V, Borlaug BA et al. Diabesity: The combined burden of obesity and diabetes on heart disease and the role of imaging. Nat Rev Cardiol. 2021;18:291-304. https://doi.org/10.1038/s41569-020-00465-5
  14. Saunders KH, Umashanker D, Igel LI, et al. Obesity pharmacotherapy. Med Clin N Am. 2018;102:135-48. https://doi.org/10.1016/j.mcna.2017.08.010
  15. Myers MG Jr, Münzberg H, Leinninger GM et al. The geometry of leptin action in the brain: More complicated than a simple ARC. Cell Metab. 2009;9:117-23. https://doi.org/10.1016/j.cmet.2008.12.001
  16. Osegbe I, Okpara H, Azinge E. Relationship between serum leptin and insulin resistance among obese Nigerian women. Ann Afr Med. 2016;15:14-19. https://doi.org/10.4103/1596-3519.158524
  17. Izquierdo AG, Crujeiras AB, Casanueva FF et al. Leptin, obesity and leptin resistance: Where are we 25 years later?. Nutrients. 2019;8:2704. https://doi.org/10.3390/nu11112704
  18. Kumar R, Mal K, Razaq M et al. Association of leptin with obesity and insulin resistance. Cureus. 2020;12(12):e12178. https://doi.org/10.7759/cureus.12178
  19. Zhang F, Chen Y, Heiman M, Dimarchi R. Leptin: Structure, function and biology. Vitam Horm. 2005;71:345-72. https://doi.org/10.1016/S0083-6729(05)71012-8
  20. Wabitsch M, Funcke JB, Lennerz B et al. Biologically inactive leptin and early-onset extreme obesity. N Engl J Med. 2015;372:48-54. https://doi.org/10.1056/NEJMoa1406653
  21. Farr OM, Gavrieli A, Mantzoros CS. Leptin applications in 2015: What have we learned about leptin and obesity? Curr Opin Endocrinol Diabetes Obes. 2015;22:353-59. https://doi.org/10.1097/MED.0000000000000184
  22. Cummings DE, Purnell JQ, Frayo RS et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001;50(8):1714-19. https://doi.org/10.2337/diabetes.50.8.1714
  23. Poher AL, Tschöp MH, Müller TD. Ghrelin regulation of glucose metabolism. Peptides. 2018;100:236-42. https://doi.org/10.1016/j.peptides.2017.12.015
  24. Kobelt P, Helmling S, Stengel A et al. Anti ghrelin SPIEGELMER NOX-B11 inhibits neurostimulatory and orexigenic effects of peripheral ghrelin in rats. Gut. 2006;55:788-92. https://doi.org/10.1136/gut.2004.061010
  25. Makris CM, Alexandrou A, Papatsoutsos GE et al. Ghrelin and obesity: Identifying gaps and dispelling myths. A reappraisal. In Vivo. 2017;31:1047-50. https://doi.org/10.21873/invivo.11168
  26. Leeners B, Geary N, Tobler PN, Asarian L. Ovarian hormones and obesity. Hum Reprod Update. 2017;23:300-21. https://doi.org/10.1093/humupd/dmw045
  27. Mangolim AS, Brito LAR, Nunes-Nogueira VS. Effectiveness of testosterone therapy in obese men with low testosterone levels, for losing weight, controlling obesity complications and preventing cardiovascular events: Protocol of a systematic review of randomized controlled trials. Medicine (Baltimore). 2018;97:e0482. https://doi.org/10.1097/MD.0000000000010482
  28. Liu F, Tu Y, Zhang P et al. Decreased visceral fat area correlates with improved total testosterone levels after Roux-en-Y gastric bypass in obese Chinese males with type 2 diabetes: A 12-month follow-up. Surg Obes Relat Dis. 2018;14:462-68. https://doi.org/10.1016/j.soard.2017.11.009
  29. Sebo ZL, Rodeheffer MS. Testosterone metabolites differentially regulate abiogenesis and fat distribution. Mol Metab. 2021;44:101141. https://doi.org/10.1016/j.molmet.2020.101141
  30. Pivonello R, Menafra D, Riccio E et al. Metabolic disorders and male hypogonadotropic hypogonadism. Front Endocrinol (Lausanne). 2019;10:345. https://doi.org/10.3389/fendo.2019.00345
  31. Fink J, Matsumoto M, Tamura Y. Potential application of testosterone replacement therapy as a treatment for obesity and type 2 diabetes in men. Steroids. 2018;138:161-66. https://doi.org/10.1016/j.steroids.2018.08.002
  32. de Freitas Junior LM, de Almeida EB Jr. Medicinal plants for the treatment of obesity: Ethnopharmacological approach and chemical and biological studies. Am J Transl Res. 2017;15(9):2050-64.
  33. Krushna K. Zambare, Arun A. Kondapure et al. A systematic review on obesity and herbal anti-obesity medicines. Research J Pharm and Tech. 2020;13(10):4966-72. https://doi.org/10.5958/0974-360X.2020.00871.9
  34. Kim HY. Effects of onion (Allium cepa) skin extract on pancreatic lipase and body weight-related parameters no title. Food Sci Biotechecnology. 2007;16:434-38.
  35. Medeiros PM, Ladio AH, Albuquerque UP. Original article Sampling problems in Brazilian research: A critical evaluation of studies on medicinal plants. Rev Bras Farmacogn. 2014;24:103-09. https://doi.org/10.1016/j.bjp.2014.01.010
  36. Bowen S, Erickson T, Martens PJ et al. More than “using research”: The real challenges in promoting evidence-informed decision-making. Healthc Policy. 2009;4:87-102. https://doi.org/10.12927/hcpol.2009.20538
  37. Huang L, Chen J, Cao P. Anti-obese effect of glucosamine and chitosan oligosaccharide in high-fat diet-induced obese rats. Mar Drugs. 2015;13:2732-56. https://doi.org/10.3390/md13052732
  38. de la Rosa LA, Moreno-Escamilla JO, Rodrigo-García J et al. Phenoliccompounds. In: EM Yahia and A Carrillo-Lopez (Eds.), Postharvest Physiology and Biochemistry of Fruits and Vegetables. 2019;pp. 253-71. https://doi.org/10.1016/B978-0-12-813278-4.00012-9
  39. Luna-Guevara ML, Luna-Guevara JJ, Hernández-Carranza P et al. Phenolic compounds: A good choice against chronic degenerative diseases. Studies in Natural Products Chemistry. 2018;59:79-108. https://doi.org/10.1016/B978-0-444-64179-3.00003-7
  40. Lee H, Jeong JH, Ryu JH. Lignan from Alnus japonica inhibits adipocyte differentiation via cell cycle and FOXO1 regulation. Molecules. 2020;25:3346. https://doi.org/10.3390/molecules25153346
  41. Mir SA, Shah MA, Ganai SA et al. Understanding the role of active components from plant sources in obesity management. J Saudi Soc Agric Sci. 2019;18:168-76. https://doi.org/10.1016/j.jssas.2017.04.003
  42. Kiss A, Takács K, Nagy A et al. In vivo and in vitro model studies on noodles prepared with antioxidant-rich pseudocereals. J Food Meas Charact. 2019;13:2696-704. https://doi.org/10.1007/s11694-019-00190-9
  43. Mayneris-Perxachs J, Alcaide-Hidalgo JM, de la Hera et al. Supplementation with biscuits enriched with hesperidin and naringenin is associated with an improvement of the metabolic syndrome induced by a cafeteria diet in rats. J Funct Foods. 2019;61:103504. https://doi.org/10.1016/j.jff.2019.103504
  44. Scazzocchio B, Minghetti L, D’Archivio M. Interaction between gut microbiota and curcumin: A new key of understanding for the health effects of curcumin. Nutrients. 2020;12:2499. https://doi.org/10.3390/nu12092499
  45. Lim KJ, Bisht S, Bar EE et al. A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol Ther. 2011;11:464-73. https://doi.org/10.4161/cbt.11.5.14410
  46. Panahi Y, Hosseini MS, Khalili N et al. Effects of supplementation with curcumin on serum adipokine concentrations: A randomized controlled trial. Nutrition. 2016;32:1116-22. https://doi.org/10.1016/j.nut.2016.03.018
  47. Hersoug LG, Møller P, Loft S. Gut microbiota-derived lipopolysaccharide uptake and trafficking to adipose tissue: Implications for inflammation and obesity. Obes Rev. 2016;17:297-312. https://doi.org/10.1111/obr.12370
  48. Islam T, Koboziev I, Albracht-Schulte K et al. Curcumin reduces adipose tissue inflammation and alters gut microbiota in diet-induced obese male mice. Mol Nutr Food Res. 2021;65:2100274. https://doi.org/10.1002/mnfr.202100274
  49. Suzuki T, Miyoshi N, Hayakawa S et al. Health benefits of tea consumption. In: Beverage Impacts on Health and Nutrition, 2nd ed.; Wilson T, Temple NJ, Eds.; Human Press: Cham, Switzerland. 2016; pp. 49-67. https://doi.org/10.1007/978-3-319-23672-8_4
  50. Wu T, Guo Y, Liu R et al. Black tea polyphenols and polysaccharides improve body composition, increase fecal fatty acid and regulate fat metabolism in high-fat diet-induced obese rats. Food Funct. 2016;7:2469-78. https://doi.org/10.1039/C6FO00401F
  51. Ashigai H, Taniguchi Y, Suzuki M et al. Fecal lipid excretion after consumption of a black tea polyphenol-containing beverage. Biol Pharm Bull. 2016;39:699-704. https://doi.org/10.1248/bpb.b15-00662
  52. Pan H, Gao Y, Tu Y. Mechanisms of body weight reduction by black tea polyphenols. Molecules. 2016;21:1659. https://doi.org/10.3390/molecules21121659
  53. Yang HY, Yang S CH, Chao J CJ et al. Beneficial effects of catechin-rich green tea and inulin on the body composition of overweight adults. Chen British Journal of Nutrition, 2012;107(5):pp. 749-54. https://doi.org/10.1017/S0007114511005095
  54. Tian C, Ye X, Zhang R et al. Green tea polyphenols reduced fat deposits in high fat-fed rats via erk1/2-PPARgamma-adiponectin pathway. PLoS One. 2013;8:e53796. https://doi.org/10.1371/journal.pone.0053796
  55. Huang J, Wang Y, Xie Z et al. The anti-obesity effects of green tea in human intervention and basic molecular studies. Eur J Clin Nutr. 2014;68:1075-87. https://doi.org/10.1038/ejcn.2014.143
  56. Li F, Gao C, Yan P et al. EGCG reduces obesity and white adipose tissue gain partly through AMPK activation in mice. Front Pharm. 2018;9:1366. https://doi.org/10.3389/fphar.2018.01366
  57. Essex K, Mosawy KS. The anti-obesity potential of green tea: The effect on leptin and adiponectin. Journal Clinical Immunology, Endocrine and Metabolic Drugs. 2017;4:14-18. https://doi.org/10.2174/2212707004666161228142812
  58. Huang LH, Liu CHY, Wang LY et al. Effects of green tea extract on overweight and obese women with high levels of low density-lipoprotein-cholesterol (LDL-C): A randomized, double-blind and cross-over placebo-controlled clinical trial. BMC Complementary and Alternative Medicine. 2018;18:294. https://doi.org/10.1186/s12906-018-2355-x
  59. Harton A, Myszkowska-Ryciak J, Gajewska D, Webb M. The role of selected bioactive compounds in teas, spices, cocoa and coffee in body weight control. Pol J Appl Sci. 2017;1:56-66.
  60. Kord-Varkaneh H, Ghaedi E, Nazary-Vanani A et al. Does cocoa/dark chocolate supplementation have a favorable effect on body weight, body mass index and waist circumference? A systematic review, meta-analysis and dose-response of randomized clinical trials. Crit Rev Food Sci Nutr. 2019;59:2349-62. https://doi.org/10.1080/10408398.2018.1451820
  61. Vernarelli JA, Lambert JD. Flavonoid intake is inversely associated with obesity and C-reactive protein, a marker for inflammation, in US adults. Nutr Diabetes. 2017;7:e276. https://doi.org/10.1038/nutd.2017.22
  62. Chaves-Ulate E, Esquivel-Rodríguez P. Chlorogenic acids present in coffee: Antioxidant and antimicrobial capacity. Agron Mesoam. 2019;30:299-311. https://doi.org/10.15517/am.v30i1.32974
  63. Polamuri D, Valentina CG, Suresh R, Islam A. In-vitro anticancer and antioxidant activity of green coffee beans extract. Asian Food Science Journal. 2020;17:24-35. https://doi.org/10.9734/afsj/2020/v17i230188
  64. Sun Z, Zhang X, Wu H et al. Antibacterial activity and action mode of chlorogenic acid against Salmonella enteritidis, a foodborne pathogen in chilled fresh chicken. World Journal of Microbiology and Biotechnology. 2020;36:24. https://doi.org/10.1007/s11274-020-2799-2
  65. Macheiner L, Schmidt A, Schreiner M et al. Green coffee infusion as a source of caffeine and chlorogenic acid. J of Food Composition and Analysis. 2019; 84:103307. https://doi.org/10.1016/j.jfca.2019.103307
  66. Dziki D, Gawlik-Dziki U, Pecio ? et al. Ground green coffee beans as a functional food supplement—Preliminary study. LWT Food Sci Technol. 2015;63:691-99. https://doi.org/10.1016/j.lwt.2015.03.076
  67. F Haidari, M Samadi, M Mohammadshahi et al. Energy restriction combined with green coffee bean extract affects serum adipocytokines and body composition in obese women. Asia Pac J Clin Nutr. 2017;26:1048-54.
  68. Roshan H, Nikpayam O, Sedaghat M et al. Effects of green coffee extract supplementation on anthropometric indices, glycaemic control, blood pressure, lipid profile, insulin resistance and appetite in patients with the metabolic syndrome: A randomized clinical trial. Br J Nutr. 2018;119:250-58. https://doi.org/10.1017/S0007114517003439
  69. Kazunari T, Shoko N, Shizuka T et al. Anti-obesity and hypotriglyceridemic properties of coffee bean extract in SD rats. Food Science Technology Res. 2019;15:147-52. https://doi.org/10.3136/fstr.15.147
  70. Xiaoyun He, Shujuan Zheng, Yao Sheng et al. Chlorogenic acid ameliorates obesity by preventing energy balance shifts in high-fat diet-induced obese mice. J of the Science of Food and Agriculture. 2020;
  71. Choi BK, Park SB, Lee DR et al. Green coffee bean extract improves obesity by decreasing body fat in high-fat diet-induced obese mice. Asian Pacific Journal of Tropical Medicine. 2016;9:635-43. https://doi.org/10.1016/j.apjtm.2016.05.017
  72. Ríos-Hoyo A, Gutiérrez-Salmeán G. New dietary supplements for obesity: What we currently know. Curr Obes Rep. 2016;5:262-70. https://doi.org/10.1007/s13679-016-0214-y
  73. Song SJ, Choi S, Park T. Decaffeinated green coffee bean extract attenuates diet-induced obesity and insulin resistance in mice. Evidence-Based Complement Altern Med. 2014;2014:1-14. https://doi.org/10.1155/2014/718379
  74. Kong L, Xu M, Qiu Y et al. Chlorogenic acid and caffeine combination attenuate adipogenesis by regulating fat metabolism and inhibiting adipocyte differentiation in 3T3-L1 cells. J Food Biochem. 2021;45:e13795. https://doi.org/10.1111/jfbc.13795
  75. Asbaghi O, Sadeghian M, Rahmani S et al. The effect of green coffee extract supplementation on anthropometric measures in adults: A comprehensive systematic review and dose-response meta-analysis of randomized clinical trials. Complementary Therapies in Medicine. 2020;51:102424. https://doi.org/10.1016/j.ctim.2020.102424
  76. Rao PV, Gan SH. Cinnamon: A multifaceted medicinal plant. Evid Based Complement Alternat Med. 2014;2014:642942. https://doi.org/10.1155/2014/642942
  77. Yazdanpanah Z, Azadi-Yazdi M, Hooshmandi H et al. Effects of cinnamon supplementation on body weight and composition in adults: A systematic review and meta-analysis of controlled clinical trials. Phytother Res. 2020;34:448-63. https://doi.org/10.1002/ptr.6539
  78. Mousavi SM, Rahmani J, Kord-Varkaneh H et al. Cinnamon supplementation positively affects obesity: A systematic review and dose-response meta-analysis of randomized controlled trials. Clin Nutr. 2020;39(1):123-33. https://doi.org/10.1016/j.clnu.2019.02.017
  79. Keramati M, Musazadeh V, Malekahmadi M. Cinnamon, an effective anti-obesity agent: Evidence from an umbrella meta-analysis. Journal of Food Biochemistry. 2022;46:e14166. https://doi.org/10.1111/jfbc.14166
  80. Ma RH, Ni ZJ, Zhu YY et al. A recent update on the multifaceted health benefits associated with ginger and its bioactive components. Food Funct. 2021;12:519-42. https://doi.org/10.1039/D0FO02834G
  81. Misawa K, Hashizume K, Yamamoto M et al. Ginger extract prevents high-fat diet-induced obesity in mice via activation of the peroxisome proliferator-activated receptor ? pathway. J Nutr Biochem. 2015;26:1058-67. https://doi.org/10.1016/j.jnutbio.2015.04.014
  82. Attari VE, Mahdavi AM, Javadivala Z et al. A systematic review of the anti-obesity and weight lowering effect of ginger (Zingiber officinale Roscoe) and its mechanismsof action. Phytother Res. 2018;32:577-85. https://doi.org/10.1002/ptr.5986
  83. Crichton M, Marshall S, Marx W et al. Efficacy of ginger (Zingiber officinale) in ameliorating chemotherapy-induced nausea and vomiting and chemotherapy-related outcomes: A systematic review update and meta-analysis. Journal of the Academy of Nutrition and Dietetics. 2019;119:2055-68. https://doi.org/10.1016/j.jand.2019.06.009
  84. Hasani H, Arab A, Hadi A et al. Does ginger supplementation lower blood pressure? A systematic review and meta-analysis of clinical trials. Phytotherapy Research. 2019;33(6):1639-47. https://doi.org/10.1002/ptr.6362
  85. Hajimoosayi F, Sadatmahalleh SJ, Kazemnejad A et al. Effect of ginger on the blood glucose level of women with gestational diabetes mellitus (GDM) with impaired glucose tolerance test (GTT): A randomized double-blind placebo-controlled trial. BMC Complementary Medicine Therapy. 2020;20:116-22. https://doi.org/10.1186/s12906-020-02908-5
  86. Maharlouei N, Tabrizi R, Lankarani KB et al. The effects of ginger intake on weight loss and metabolic profiles among overweight and obese subjects: A systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 2019;59:1753-66. https://doi.org/10.1080/10408398.2018.1427044
  87. Park SH, Jung SJ, Choi EK et al. The effects of steamed ginger ethanolic extract on weight and body fat loss: A randomized, double-blind, placebo-controlled clinical trial. Food Sci Biotechnol. 2020;29:265-73. https://doi.org/10.1007/s10068-019-00649-x
  88. Ayaz A, Roshan VD. Effects of 6-weeks water-based intermittent exercise with and without Zingiber officinale on pro-inflammatory markers and blood lipids in overweight women with breast cancer. J Appl Pharm Sci. 2012;2:218-24. https://doi.org/10.7324/JAPS.2012.2547
  89. Khosravani M, Azerbaijani MA, Abolmaesoomi M et al. Ginger extract and aerobic training reduce lipid profile in high-fat fed diet rats. Eur Rev Med Pharmacol Sci. 2016; 20:1617-22.
  90. Seo SH, Fang F, Kang I. Ginger (Zingiber officinale) attenuates obesity and adipose tissue remodeling in high-fat diet-fed C57BL/6 mice. Int J Environ Res Public Health. 2021;13(18):631. https://doi.org/10.3390/ijerph18020631
  91. Jafarzadeh A, Nemati M. Therapeutic potentials of ginger for the treatment of multiple sclerosis: A review with emphasis on its immunomodulatory, anti-inflammatory and anti-oxidative properties. J Neuroimmunol. 2018;324:54-75. https://doi.org/10.1016/j.jneuroim.2018.09.003
  92. Apovian CM, Aronne LJ, Bessesen DH et al. Pharmacological management of obesity: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:342-62. https://doi.org/10.1210/jc.2014-3415
  93. Masterson JM, Soodana-Prakash N, Patel AS et al. Elevated body mass index is associated with secondary hypogonadism among men presenting to a tertiary academic medical center. World J Mens Health. 2019;37:93-98. https://doi.org/10.5534/wjmh.180047
  94. US Department of Health and Human Services, Food and Drug Administration: Guidance for Industry Developing Products for Weight Management. Available from: https://www.fda. gov/media/71252/download (cited 2020 Dec 8).
  95. Srivastava G, Apovian CM. Current pharmacotherapy for obesity. Nat Rev Endocrinol. 2018;14:12-24. https://doi.org/10.1038/nrendo.2017.122
  96. Lee SY, Park HS, Kim DJ et al. Appropriate waist circumference cutoff points for central obesity in Korean adults. Diabetes Res Clin Pract. 2007;75:72-80. https://doi.org/10.1016/j.diabres.2006.04.013
  97. Curioni CC, Lourenço PM. Long-term weight loss after diet and exercise: A systematic review. Int J Obes (Lond). 2005;29:1168-74. https://doi.org/10.1038/sj.ijo.0803015
  98. Garvey WT, Mechanick JI, Brett EM et al. American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22:1-203. https://doi.org/10.4158/EP161365.GL
  99. Bhat SP, Sharma A. Current drug targets in obesity pharmacotherapy -A review. CurrDrug Targets. 2017;18:983-93. https://doi.org/10.2174/1389450118666170227153940
  100. Coulter AA, Rebello CJ, Greenway FL. Centrally acting agents for obesity: Past, present and future. Drugs. 2018;78:1113-32. https://doi.org/10.1007/s40265-018-0946-y
  101. Daneschvar HL, Aronson MD, Smetana GW. FDA-approved anti-obesity drugs in the united states. Am J Med. 2016 Aug;129(8):879.e1-6. doi: 10.1016/j.amjmed.2016.02.009.
  102. Kakkar AK, Dahiya N. Drug treatment of obesity: Current status and prospects. Eur J Intern Med. 2015;26:89-94. https://doi.org/10.1016/j.ejim.2015.01.005
  103. Apovian CM, Garvey WT, Ryan DH. Challenging obesity: Patient, provider and expert perspectives on the roles of available and emerging nonsurgical therapies. Obesity (Silver Spring). 2015;23:S1-26. https://doi.org/10.1002/oby.21140
  104. Garcia SB, Barros LT, Turatti A et al. The anti-obesity agent Orlistat is associated with an increase in colonic preneoplastic markers in rats treated with a chemical carcinogen. Cancer Lett. 2006;240:221-24. https://doi.org/10.1016/j.canlet.2005.09.011
  105. Shirai K, Tanaka M, Fujita T et al. Reduction of excessive visceral fat and safety with 52-week administration of lipase inhibitor orlistat in Japanese: Long-term clinical study. Adv Ther. 2019;36:217-31. https://doi.org/10.1007/s12325-018-0822-x
  106. Dailey MJ, Moran TH. Glucagon-like peptide 1 and appetite. Trends Endocrinol Metab. 2013;24:85-91. https://doi.org/10.1016/j.tem.2012.11.008
  107. O’Neil PM, Birkenfeld AL, McGowan B et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: A randomised, double-blind, placebo and active controlled, dose-ranging, Phase 2 trial. Lancet. 2018;392:637-49. https://doi.org/10.1016/S0140-6736(18)31773-2
  108. Neeland IJ, Marso SP, Ayers CR et al. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: A randomised, double-blind, placebo-controlled, clinical trial. Lancet Diabetes Endocrinol. 2021;9:595-605. https://doi.org/10.1016/S2213-8587(21)00179-0
  109. Ladenheim EE. Liraglutide and obesity: A review of the data so far. Drug Des Dev Therapy. 2015;2015:1867-75. https://doi.org/10.2147/DDDT.S58459
  110. Rubino DM, Greenway FL, Khalid U et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 Randomized Clinical Trial. JAMA—J Am Med Assoc. 2022;327:138-50. https://doi.org/10.1001/jama.2021.23619
  111. Macêdo APA, Vieira RFL, Brisque GD. Liraglutide and exercise: A possible treatment for obesity? Obesities. 2022;2:285-91. https://doi.org/10.3390/obesities2030023112.
  112. O'Neil PM, Smith SR, Weissman NJ et al. A randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: The BLOOMDM study. Obesity (Silver Spring). 2012;20:1426-36. https://doi.org/10.1038/oby.2012.66
  113. Meltzer HY, Roth BL. Lorcaserin and pimavanserin: Emerging selectivity of serotonin receptor subtype-targeted drugs. J Clin Invest. 2013;123:4986-91. https://doi.org/10.1172/JCI70678
  114. Greenway FL, Shanahan W, Fain R et al. Safety and tolerability review of lorcaserin in clinical trials. Clin Obes. 2016;6:285-95. https://doi.org/10.1111/cob.12159
  115. Bohula EA, Scirica BM, Inzucchi SE et al. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): A randomized, placebo-controlled trial. Lancet. 2018;392:2269-79. https://doi.org/10.1016/S0140-6736(18)32328-6
  116. Safety clinical trial shows a possible increased risk of cancer with weight-loss medicine Belviq, Belviq XR (lorcaserin). FDA Drug Safety Communication issued on 2-13-2020.
  117. de Andrade Mesquita L, Fagundes Piccoli G, Richter da Natividade G et al. Is lorcaserin associated with an increased risk of cancer? A systematic review and meta-analysis. Obes Rev. 2021;22:e13170. https://doi.org/10.1111/obr.13170
  118. Miles KE, Kerr JL. Semaglutide for the treatment of type 2 diabetes mellitus. J Pharm Technol. 2018;34:281-89. https://doi.org/10.1177/8755122518790925
  119. Canadian agency for drugs and technologies in health. CADTH common drug review: Pharmacoeconomic review report: semaglutide (Ozempic) (Novo Nordisk Canada Inc.). 2019; Accessed May 2, 2022.
  120. US food and drug administration. FDA approves new drug treatment for chronic weight management, first since 2014. June 4, 2021; Accessed May 2, 2022.
  121. Ghusn W, la Rosa AD, Sacoto D et al. Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Network Open. 2022;5:e2231982. https://doi.org/10.1001/jamanetworkopen.2022.31982
  122. Fonseca VA, Capehorn MS, Garg SK et al. Insulin resistance reduction is mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide. J Clin Endocrinol Metab. 2019;104:4078-86. https://doi.org/10.1210/jc.2018-02685
  123. Christou GA, Katsiki N, Blundell J et al. Semaglutide is a promising anti-obesity drug. Obes Rev. 2019;20:805-15. https://doi.org/10.1111/obr.12839
  124. Blundell J, Finlayson G, Axelsen M et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19:1242-51. https://doi.org/10.1111/dom.12932
  125. Gaykema RP, Newmyer BA, Ottolini M et al. Activation of murine pre-proglucagon-producing neurons reduces food intake and body weight. J Clin Invest. 2017;127:1031-45. https://doi.org/10.1172/JCI81335
  126. Krieger JP, Arnold M, Pettersen KG et al. Knockdown of GLP-1 receptors in vagal afferents affects normal food intake and glycemia. Diabetes. 2016;65:34-43. https://doi.org/10.2337/db15-0973
  127. Davies M, Færch L, Jeppesen OK et al. Semaglutide 2· 4 mg once a week in adults with overweight or obesity and type 2 diabetes (STEP 2): A randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397:971-84. https://doi.org/10.1016/S0140-6736(21)00213-0
  128. Wharton S, Calanna S, Davies M et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24:94-105. https://doi.org/10.1111/dom.14551
  129. Garvey?WT, Batterham? RL, Bhatta M. Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nat Med. 2022 Oct;28(10):2083-91. doi: 10.1038/s41591-022-02026-4.
  130. Wilding JP. Combination therapy for obesity. J Psychopharmacol. 2017;31:1503-08. https://doi.org/10.1177/0269881117737401
  131. Final appraisal determination. Naltrexone–bupropion for managing overweight and obesity. National Institute for Health and Care Excellence. Issue date: July 2017.
  132. Wang GJ, Tomasi D, Volkow ND et al. Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues. Int JObes (Lond). 2014;38:682-88. https://doi.org/10.1038/ijo.2013.145
  133. Onakpoya IJ, Lee JJ, Mahtani KR et al. Naltrexone-bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports. Br J Clin Pharmacol. 2020;86:646-67. https://doi.org/10.1111/bcp.14210
  134. . Matyjaszek-Matuszek B, Szafraniec A, Porada D. Pharmacotherapy of obesity - state of the art. Endokrynol Pol. 2018;69. https://doi.org/10.5603/EP.2018.0048
  135. Patel DK, Stanford FC. Safety and tolerability of new-generation anti-obesity medications: A narrative review. Postgrad Med. 2018;130:173-82. https://doi.org/10.1080/00325481.2018.1435129
  136. Rothman RB, Baumann MH. Appetite suppressants, cardiac valve disease and combination pharmacotherapy. Am J Ther. 2009;16:354-64. https://doi.org/10.1097/MJT.0b013e31817fde95
  137. Velazquez A, Apovian CM. Updates on obesity pharmacotherapy. Ann N Y Acad Sci. 2018;1411:106-19. https://doi.org/10.1111/nyas.13542
  138. Gadde KM, Allison DB, Ryan DH et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomized, placebo-controlled, phase 3 trial. Lancet (London, England). 2011;16(377):1341-52. https://doi.org/10.1016/S0140-6736(11)60205-5
  139. Incecik F, Hergüner MO, Altunba?ak S. Hypohidrosis and hyperthermia during topiramate treatment in children. The Turkish Journal of Pediatrics. 2012;54:515-18.
  140. Duy PQ, Krauss GL, Crone NE et al. Antiepileptic drug withdrawal and seizure severity in the epilepsy monitoring unit. Epilepsy and Behavior: E and B. 2020;109:107128. https://doi.org/10.1016/j.yebeh.2020.107128
  141. Parasuraman S, Thing GS, Dhanaraj SA. Polyherbal formulation: Concept of ayurveda. Pharmacognosy Reviews. 2014;8:73-80. https://doi.org/10.4103/0973-7847.134229
  142. Liu Y, Sun M, Yao H et al. Herbal medicine for the treatment of obesity: An overview of scientific evidence from 2007 to 2017. Evidence-based Complementary and Alternative Medicine. 2017;2017:17. https://doi.org/10.1155/2017/8943059
  143. Gupte P, Harke S, Deo V et al. A clinical study to evaluate the efficacy of herbal formulation for obesity (HFO-02) in overweight individuals. Journal of Ayurveda and Integrative Medicine. 2020;11:159-62. https://doi.org/10.1016/j.jaim.2019.05.003
  144. Pandeya PR, Lamichhane R, Lamichhane G et al. 18KHT01, a potent anti-obesity polyherbal formulation. Frontiers in Pharmacology. 2021;12:807081. https://doi.org/10.3389/fphar.2021.807081
  145. Cv C, Ma V, Vs B. Herbal approach for obesity management. American Journal of Plant Sciences. 2012;2012.
  146. Lamichhane G, Pandey PR. Regulatory aspects of nutraceuticals and functional foods in Nepal. Functional Foods and Novel Foods: International Journal on Nutraceuticals; 2020.
  147. Taghizadeh M, Farzin N, Taheri S et al. The effect of dietary supplements containing green tea, capsaicin and ginger extracts on weight loss and metabolic profiles in overweight women: A randomized double-blind placebo-controlled clinical trial. Ann Nutr Metab. 2017;70:277-85. https://doi.org/10.1159/000471889
  148. Dhuha A Alshammaa, Zainab AA Alshamma, Ammar Amer. Phytochemical comparison study for evaluating the hypolipidemic effect between two Iraqi pepper spp. in the rats Model. Biomed and Pharmacol J. 2022;15:2421-35. https://doi.org/10.13005/bpj/2580
  149. Tremblay, Arguin, Panahi. Capsaicinoids a spicy solution to the management of Obesity. Int J Obes. 2018;40:1198-204. https://doi.org/10.1038/ijo.2015.253
  150. Pandeya PR, Lamichhane G et al. Antiobesity activity of two polyherbal formulations in high-fat diet-induced obese C57BL/6J mice. Biomed Res Int. 2022 May 11;2022:9120259. https://doi.org/10.1155/2022/9120259
  151. Mahnaz K, Radzi CWJWM, Cordell GA et al. Potential of traditional medicinal plants for treating obesity: A review. International Conference on Food Science and Nutrition (ICNFS). 2012;23-24.
  152. Heber D. Herbal preparations for obesity: Are they useful? Primary care. 2003;30:441-63. https://doi.org/10.1016/S0095-4543(03)00015-0
  153. Vermaak I, Viljoen AM, Hamman JH. Natural products in anti-obesity therapy. Natural Product Reports. 2011;28:1493-533. https://doi.org/10.1039/c1np00035g
  154. Sui Y, Zhao H, Wong V et al. A systematic review on the use of Chinese medicine and acupuncture for treatment of obesity. Obesity Reviews. 2012;13:409-30. https://doi.org/10.1111/j.1467-789X.2011.00979.x
  155. Kumar MM, Kaushik D, Kaur J. Critical review on obesity: Herbal approach, bioactive compounds and their mechanism. Appl Sci. 2022;12:8342. https://doi.org/10.3390/app12168342
  156. Salehi B, Ata A, V Anil Kumar N, Sharopov F et al. Antidiabetic potential of medicinal plants and their active components. Biomolecules. 2019;9:551. https://doi.org/10.3390/biom9100551
  157. B Saad, H Zaid, S Shanak et al. Anti-diabetes and antiobesity medicinal plants and phytochemicals safety, efficacy and action mechanisms. Springer, Berlin, Germany. 2017;ISBN 978-3-319-54101-3, ISBN 978-3-319-54102-0 (eBook) chapter 5.
  158. R Farrington, IF Musgrave, RW Byard. Evidence for the efficacy and safety of herbal weight loss preparations. Journal of Integrative Medicine. 2019;17:pp. 87-92. https://doi.org/10.1016/j.joim.2019.01.009
  159. Delimont NM, Haub MD, Lindshield BL. The impact of tannin consumption on iron bioavailability and status: A narrative review. Curr Dev Nutr. 2017;19(1):1-12. https://doi.org/10.3945/cdn.116.000042
  160. Hayat K, Iqbal H, Malik U et al. Tea and its consumption: Benefits and risks. Critical Reviews in Food Science and Nutrition. 2015;55:939-54. https://doi.org/10.1080/10408398.2012.678949
  161. Miyoshi N, Pervin M, Suzuki T et al. Green tea catechins for well-being and therapy: Prospects and opportunities. Bot Targets Ther. 2015;5:85-96. https://doi.org/10.2147/BTAT.S91784
  162. Wang S, Moustaid-Moussa N, Chen L et al. Novel insights of dietary polyphenols and obesity. J Nutr Biochem. 2014;25. https://doi.org/10.1016/j.jnutbio.2013.09.001
  163. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: A systematic and clinical review. JAMA. 2014;311:74-86. https://doi.org/10.1001/jama.2013.281361
  164. Khera R, Murad MH, Chandar AK et al. Association of pharmacological treatments for obesity with weight loss and adverse events. A systematic review and meta-analysis. JAMA. 2016;315:2424-34. https://doi.org/10.1001/jama.2016.7602
  165. US. Food and drug administration. Beware of Fraudulent Weight-Loss 'Dietary Supplements'. Accessed Jun 22, 2021.
  166. Ruangaram W, Kato E. Selection of thai medicinal plants with anti-obesogenic potential via in vitro methods. Pharmaceuticals. 2020;13:56. https://doi.org/10.3390/ph13040056

Downloads

Download data is not yet available.